Regenxbio (RGNX) Share-based Compensation (2014 - 2025)

Regenxbio's Share-based Compensation history runs 12 years deep, the most recent figure standing at $8.4 million for Q4 2025.

• In Q4 2025, Share-based Compensation fell 12.23% year-over-year to $8.4 million; the TTM figure through Dec 2025 stood at $34.6 million (down 10.14% YoY), while the FY2025 annual figure was $34.6 million, down 10.14% from the prior year.
• Share-based Compensation was $8.4 million for Q4 2025 at Regenxbio, down from $9.0 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $11.2 million in Q1 2023 to a low of $8.3 million in Q4 2023.
• Historically, Share-based Compensation has averaged $9.6 million across 5 years, with a median of $9.7 million in 2021.
• The sharpest annual moves came in 2021 and 2024: Share-based Compensation rose 23.74% in 2021, then fell 14.31% in 2024.
• A 5-year view of Share-based Compensation shows it stood at $9.2 million in 2021, then advanced by 2.69% to $9.4 million in 2022, then retreated by 11.37% to $8.3 million in 2023, then increased by 14.44% to $9.5 million in 2024, then decreased by 12.23% to $8.4 million in 2025.
• The last three Share-based Compensation figures came in at $8.4 million (Q4 2025), $9.0 million (Q3 2025), and $8.7 million (Q2 2025), per Business Quant data.